Literature DB >> 17299603

Neutrophilic inflammation as a major determinant in the progression of cystic fibrosis.

Rabindra Tirouvanziam1.   

Abstract

Cystic fibrosis (CF) is the most frequent recessive disease in Caucasians. While CF affects all exocrine organs throughout the body, its lung manifestation represents the main cause of morbidity and mortality. Key studies have demonstrated that neutrophilic inflammation occurs early in the course of CF lung disease and that neutrophil-derived factors, most notably elastase, play a crucial pathological role. However, the exact mechanism of neutrophilic inflammation remains unclear. Are there distinct inflammatory phases in the multidecade-long course of CF lung disease? Are CF neutrophils intrinsically abnormal or conditioned by neighboring cells? What is the role of live versus post-apoptotic lung neutrophils? These are some of the questions that this review addresses. This review also argues that the current paradigm that views neutrophils as short-lived indiscriminate killers is seriously flawed. Thus, researchers and clinicians need to view the pathophysiological importance of neutrophils in a new light, to the ultimate benefit of patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17299603     DOI: 10.1358/dnp.2006.19.10.1068008

Source DB:  PubMed          Journal:  Drug News Perspect        ISSN: 0214-0934


  15 in total

1.  SB-656933, a novel CXCR2 selective antagonist, inhibits ex vivo neutrophil activation and ozone-induced airway inflammation in humans.

Authors:  Aili L Lazaar; Lisa E Sweeney; Alexander J MacDonald; Neil E Alexis; Chao Chen; Ruth Tal-Singer
Journal:  Br J Clin Pharmacol       Date:  2011-08       Impact factor: 4.335

2.  Altered phosphorylated signal transducer and activator of transcription profile of CD4+CD161+ T cells in asthma: modulation by allergic status and oral corticosteroids.

Authors:  Yael Gernez; Rabindra Tirouvanziam; Khoa D Nguyen; Leonard A Herzenberg; Alan M Krensky; Kari C Nadeau
Journal:  J Allergy Clin Immunol       Date:  2007-10-24       Impact factor: 10.793

3.  Activation of critical, host-induced, metabolic and stress pathways marks neutrophil entry into cystic fibrosis lungs.

Authors:  Megha Makam; Daisy Diaz; Julie Laval; Yael Gernez; Carol K Conrad; Colleen E Dunn; Zoe A Davies; Richard B Moss; Leonore A Herzenberg; Leonard A Herzenberg; Rabindra Tirouvanziam
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-17       Impact factor: 11.205

4.  Profound functional and signaling changes in viable inflammatory neutrophils homing to cystic fibrosis airways.

Authors:  Rabindra Tirouvanziam; Yael Gernez; Carol K Conrad; Richard B Moss; Iris Schrijver; Colleen E Dunn; Zoe A Davies; Leonore A Herzenberg; Leonard A Herzenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-11       Impact factor: 11.205

Review 5.  Dual PDE3/4 inhibitors as therapeutic agents for chronic obstructive pulmonary disease.

Authors:  Katharine H Banner; Neil J Press
Journal:  Br J Pharmacol       Date:  2009-06-05       Impact factor: 8.739

6.  CFTR and Ca Signaling in Cystic Fibrosis.

Authors:  Fabrice Antigny; Caroline Norez; Frédéric Becq; Clarisse Vandebrouck
Journal:  Front Pharmacol       Date:  2011-10-25       Impact factor: 5.810

7.  The Role of Human Beta-Defensin-2 in Pseudomonas aeruginosa Pulmonary Infection in Cystic Fibrosis Patients.

Authors:  Daniel Dalcin; Marina Ulanova
Journal:  Infect Dis Ther       Date:  2013-10-19

8.  Stochastic tracking of infection in a CF lung.

Authors:  Sara Zarei; Ali Mirtar; Forest Rohwer; Peter Salamon
Journal:  PLoS One       Date:  2014-10-31       Impact factor: 3.240

9.  One-pot efficient synthesis of N(α)-urethane-protected β- and γ-amino acids.

Authors:  Marta Cal; Mariusz Jaremko; Łukasz Jaremko; Piotr Stefanowicz
Journal:  Amino Acids       Date:  2012-12-19       Impact factor: 3.520

10.  Reduced neutrophil elastase inhibitor elafin and elevated transforming growth factor-β1 are linked to inflammatory response in sputum of cystic fibrosis patients with Pseudomonas aeruginosa.

Authors:  Jan C Thomassen; Tobias Trojan; Maxine Walz; Christina Vohlen; Gregor Fink; Ernst Rietschel; Miguel A Alejandre Alcazar; Silke van Koningsbruggen-Rietschel
Journal:  ERJ Open Res       Date:  2021-07-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.